Umoja and AbbVie chase Interius with in vivo Car-T
The companies hopes to be as efficacious as ex vivo therapy, with convenience and safety advantages.
The companies hopes to be as efficacious as ex vivo therapy, with convenience and safety advantages.
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Imbruvica faces challenges on multiple fronts.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.